Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
CT-P47 (tocilizumab biosimilar) Developer: Celltrion Modality: Monoclonal antibody PDUFA Date: No later than January 28, 2025 Indication/Description: Immunology / A biosimilar to Actemra (tocilizumab) for rheumatoid arthritis and juvenile idiopathic arthritis
Dose Strength Higherdose formulations (1 mg, 2 mg) require proportionally more API, increasing perunit cost
The peptide is supplied as a lyophilized, water-soluble powder that must be reconstituted before use
FDA Consumer Alert: Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss (October 2023) 4
US$ 20.34
US$ 23.77
US$ 24.43
